Is Zepbound a Semaglutide? Brand Names vs Molecules

No, Zepbound is not a semaglutide. It is tirzepatide, the same molecule as Mounjaro. Wegovy and Ozempic are both semaglutide. Rybelsus is semaglutide too, in a tablet. Seven familiar brand names cover four molecules, and knowing which is which is the difference between reading a price correctly and being sold something on a trial result that was never about it.

This is not pedantry. Almost every confusing thing in this market — why two drugs cost the same, why your insurer covers one and not the other, why a compounded seller quotes a number from a trial they were not in — comes back to the gap between a brand and the substance inside it.

The whole map, on one table

The pattern is consistent: each manufacturer took one molecule and gave it two names, one for the diabetes label and one for the weight label. Same drug, same factory, different box, and frequently a very different price and coverage outcome.

Where this actually costs you money

1. Coverage follows the label, not the molecule. A plan that excludes weight-management drugs may still cover the diabetes-labeled twin — for a diabetes diagnosis. Which name is on the prescription can decide whether it is paid for.
2. Manufacturer cash programs differ by brand. Wegovy and Zepbound have direct-pay tiers around $349–$499. Ozempic and Mounjaro largely do not, and list far higher. Same molecules.
3. Trial results attach to a dose, not a name. Ozempic tops out at 2 mg for diabetes; Wegovy climbs to 2.4 mg for weight. Quoting weight-loss figures from one at the doses of the other overstates what you should expect.
4. Compounded sellers sell the MOLECULE. Nobody is selling you compounded Zepbound. They are selling compounded tirzepatide, which is a different product with different oversight — and often quoting Zepbound’s trial number next to it.

Which of these is a pill?

Two, and neither is tirzepatide. Rybelsus is oral semaglutide, approved for type 2 diabetes, and it needs a strict fasting window because a peptide barely survives the gut without help. Foundayo is orforglipron, approved in April 2026 for weight management — a non-peptide small molecule, which is why it does not need the same food rules.

There is no oral tirzepatide. If a seller offers you “tirzepatide tablets” or a sublingual version, they are offering a compounded preparation with no approved counterpart and therefore no bioavailability standard to measure it against — nobody can tell you what fraction of the dose reaches your bloodstream. And whatever you are offered, it is not a patch, because a peptide that size does not cross skin.

Things sold beside these that are not GLP-1s at all

Peptide sellers frequently list these next to GLP-1s, which invites the assumption that they belong to the same family. They do not.

• Tesamorelin (EGRIFTA) — a growth hormone-releasing factor analog, approved for HIV-associated lipodystrophy, with a label that says it is not indicated for weight loss management.
• BPC-157 — not approved for anything, and not on the list a compounding pharmacy may lawfully use.
• Retatrutide — a genuine Lilly candidate, still in phase 3 trials and not approved, whatever is being sold under the name.
• Sermorelin, ipamorelin, AOD-9604 — growth-hormone-axis peptides, not incretin drugs. Different mechanism, different evidence, and none of them approved for weight loss.

Common questions

Take it further

Every pairing has its own page with the trial figures, the manufacturer pricing and what the compounded market charges for each molecule — start with Wegovy against Zepbound or Mounjaro against Zepbound, and the glossary covers the vocabulary sellers use around all of it.